Sweis et al. reported that BLCA with FGFR3 alterations were enriched in non–T-cell-inflamed tumors (poor T-cell infiltration) in the TCGA cohort and speculated the impaired response of CPIs in BLCA with aFGFR3 [18]. This evidence concerns the gene FGFR3 and bladder transitional cell carcinoma.